肾血管性高血压的介入治疗

目的：研究经皮腔内血管成形术加内支架植入术治疗肾动脉狭窄致致肾血管性高山压的临床效果。方法：选用Palmaz支架,对7例大动脉炎、2例动脉弱样硬化,3例纤维肌性发育不良所致肾动脉病变先行经皮腔内血管成形术,然后放置支架,术后患者行常规抗凝治疗,结果：12例患者,经皮腔内血管成形术加支架植入术技术成功率为100％,血压下降60－120／35－100mmHg近期随访－32个月未见复发,结论：经皮腔内血管成形术加支架植入术治疗肾血管性管高血压效果满意,创伤小,患者痛苦少,为肾动脉狭窄所致肾血管性高血压较理想的治疗方法。     

移植肾动脉狭窄腔内治疗的中期结果

目的探讨移植肾动脉狭窄经皮血管腔内成形(PTA)及支架置入的安全性及中远期结果。方法回顾性分析2011年1月至2018年12月解放军总医院血管外科收治的18例移植肾动脉狭窄患者的临床资料。结果3例经同侧股动脉,15例经对侧股动脉人路治疗。4例单纯PTA治疗,8例PTA后置入支架,6例直接置入支架。共置入14枚支架,均为球扩式支架,其中2枚为药涂支架,技术成功率100%。平均造影剂用量64ml,治疗前肾动脉狭窄率为50%〜99%,腔内治疗后狭窄率降为10%〜30%。收缩压由术前的(157.2±43.0)mmHg降至术后的(129.8±8.6)mmHg;血清肌酐(SCr)水平由术前的(258.8±214.7)μmol/L降至术后的(176.3±101.1)μmol/L,尿素氮由术前的(15.7±1.6)mmol/L降至术后(10.6±1.1)mmol/L(均P<0.05)。术后中位随访42.4个月(3~93个月),治愈17例,无效1例,1例单纯球囊扩张后术后30 d出现再狭窄,予以置入支架。除1例移植肾动脉出血外无其他并发症。结论移植肾动脉狭窄是导致移植肾失功的常见血管因素,腔内治疗安全、有效。     

肾动脉狭窄80例外科治疗

目的 探讨肾动脉狭窄外科治疗方法的选择和疗效.方法 回顾性分析1997年11月到2008年8月80例肾动脉狭窄患者的外科治疗经验.男性53例,女性27例,年龄9～80岁.病变包括动脉硬化42例,大动脉炎23例,肌纤维发育不良11例.共接受外科治疗83人次,其中腹主动脉肾动脉旁路术13例,自体肾移植术5例,肾切除术1例,肾动脉内膜切除术1例,肾动脉狭窄段切除吻合术1例,球囊扩张术14例,支架成形术48例.结果 围手术期死亡1例.63例获得随访,随访时间1～129个月,2例死亡.随访患者血压(135.7±15.8)/(80.1±8.5)mm Hg(1 mm Hg=0.133kPa),较术前(149.8±18.3)/(88±13.6)mm Hg下降(P<0.01).总的降压有效率为65.6%,动脉硬化、大动脉炎、肌纤维发育不良患者的降压有效率分别为50%、73.3%和100%(P<0.05).随访患者肌酐(112.7±53.6)/μmol/L,低于术前(131.7±91.7)μmol/L(P<0.05).结论 肾动脉狭窄通过外科治疗可以有效改善血压和肾功能,动脉硬化病变首选支架成形,肌纤维发育不良性病变首选球囊扩张,大动脉炎性病变首选手术治疗.     

肾移植后肾功脉狭窄:一种可能的免疫现象

肾动脉狭窄是肾移植最常见的血管并发症,发病率为1～25%,病因包括受体动脉硬化、肾灌洗时肾动脉损伤、错误的血管吻合及肾动脉纽转的受压,但免疫学因素未引起足够重视。作者对4年间连续100例肾移植进行回顾性分析,供肾采用整块原位Collins,液灌洗法并置于右髂窝。9例随访表明继发性高血压或原有高血压恶化(降压治疗无效),该9例(Ⅰ组)与年龄和术后时间类似的40例(Ⅱ组)作对照,并比较两组供者年龄,HLA配型程度,急、慢性排斥发病率和肾功能,同时分析了Ⅰ组血管杂音,狭窄的类型、位置、发病时间以及肾动脉狭窄成形术(8例经皮经管腔血管成形术,1例手术切除狭窄血管段后再吻合)后对血压肾功能恢复的效     

经皮穿刺血管成形术治疗移植肾动脉狭窄

为了观察血管成形术在移植肾动脉狭窄的治疗作用。我们将18例移植肾动脉狭窄并高血压的患者进行了血管成形术治疗。疗效以临床随访、血管造影和超声追踪为评价。结果18例患者手术均成功，成形术后，所有患者均治愈。认为血管成形术是移植肾动脉狭窄所致长期高血压和肾功能减退的有效的和首选的治疗方法。     

经皮穿剌血管盛开术治疗移植肾动脉狭窄

为了观察血管成形术在移植肾动脉狭窄的治疗作用。我们将１８例移植肾动脉狭窄并高血压的患者进行了血管成形术治疗。疗效以临床随访、血管造影和超声迫踪为评价。结果１８例患者手术均成功，成形术后，所有患者均治愈。认为血管成形术是移植肾动脉狭窄所致长期高血压和肾功能减退的有效的和首选的治疗方法。     

肾动脉狭窄合并高血压及肾功能不全患者行血运重建的中期疗效评价

目的评价经皮肾动脉血运重建术(percutaneous transluminal renal artery revascularization,PTRAR)治疗对肾动脉狭窄合并高血压及肾功能不全患者的临床疗效。方法对2011年1月至2015年6月因肾动脉狭窄合并高血压在华中科技大学同济医学院附属同济医院心内科行肾动脉血运重建术的62例患者进行回顾性研究,并对其中18例肾功能不全的患者进行随访观察。结果62例患者共76条肾动脉严重狭窄或闭塞,均成功开通,14条肾动脉仅行球囊扩张,62条肾动脉行支架置入。住院期间未出现任何手术相关并发症;术后24 h血压也有明显的下降[收缩压:(150.8±16.4)mmHg比(132.0±12.8)mmHg;舒张压:(88.6±12.7)mmHg比(80.1±11.1)mmHg,P均0.05]。术后24 h肾功能不全的18例患者平均血压降至(135.7±16.0)/(83.8±11.4)mmHg。针对18例肾功能不全的患者,术后平均随访26个月,结果发现,与术前相比血压明显下降[收缩压:(138.4±11.8)mmHg比(148.7±9.1)mmHg;舒张压:(88.1±10.7)mmHg比(93.5±9.5)mm·Hg,P均0.05]。所有62例患者术后服药种数明显减少。18例肾功能不全者中6例(33.3%)治愈,7例(38.9%)改善,5例(27.8%)无变化;术后血清肌酐水平的监测发现9例患者的肾功能好转,6例患者的肾功能未受明显影响,3例患者的肾功能恶化。结论肾动脉血运重建术对肾动脉狭窄合并高血压患者的血压带来明显的获益,但对肾功能的改善效果有待进一步研究。     

经皮血管成形术治疗移植肾动脉狭窄的临床分析

目的 探讨经皮血管成形术(PTA)治疗移植肾动脉狭窄(TRAS)的效果及预后.方法 回顾性分析白2002年4月至2008年12月经肾动脉造影检查证实为TRAS的10例患者临床资料.术前患者均接受血液透析治疗;术后采用三联免疫抑制治疗方案;初步诊断TRAS采用彩超检查方法,确诊应用移植肾动脉造影方式;采用PTA治疗10例移植肾动脉狭窄患者,观察治疗效果及患者预后.结果 10例患者经PTA治疗后均获临床治愈,其中8例术后血压及移植肾功能显著改善,2例术后发生肾功能延迟恢复(DGF),经血液透析治疗后肾功能恢复良女子.结论 PTA是治疗TRAS的安全、有效的方法,PTA治疗后出现的DGF是可以治愈的.     

血管内支架成形术治疗肾动脉狭窄的临床研究

目的探讨血管内支架成形术治疗肾动脉狭窄的安全性及临床疗效。方法回顾性分析2008年8月~2015年9月我院行血管内支架置入术的85例肾动脉狭窄患者临床资料,观察其手术成功率、围手术期并发症发生率及临床疗效。结果 85例患者共成功植入85枚球扩式肾动脉支架,手术成功率100%。围手术期未发生动脉夹层、支架内血栓形成、急性肾功能衰竭等并发症。术后血压较术前呈逐渐下降趋势,服用降压药数减少,肾功能-血肌酐稳定。85例患者随访6个月~7年,平均(21.3±18.4)个月。随访期间发现肾动脉再狭窄8例(9.4%),均为无症状性狭窄。无责任血管相关的肾功能恶化。结论血管内支架成形术治疗肾动脉狭窄能解除血管狭窄,可有效改善血压,防止肾功能恶化,是一种安全有效的治疗方法。     

经皮腔内血管成形术及支架治疗儿童和青少年肾动脉狭窄短期及长期疗效

目的 评估经皮经腔内血管成形术(PTA)及支架治疗儿童和青少年肾动脉狭窄的短期及长期疗效.方法 分析34例接受PTA及支架治疗的儿童和青少年肾动脉狭窄患者,并分为肌纤维发育不良(FMD,n=17)和大动脉炎(TA,n=17)两组,术后短期(围手术期< 30天)、3、6、12个月进行随访,之后每隔1年随访.记录介入治疗前及随访期血压,采用限定每日剂量(DDD)比较介入治疗前后药物剂量变化,比较介入治疗前后血肌酐水平,并比较两组的疗效.结果 34例患者(40支病变肾动脉)接受PTA,手术成功率为90.00%(36/40).随访中位时间30.0个月.随访期间血压较术前明显下降(P <0.001).患者术后短期DDD较术前无明显变化(P >0.05);但术后3个月、1年、3年、5年较术前差异有统计学意义(P <0.05).随访期间平均血肌酐较术前无明显变化(P >0.05).患者术后1年、3年、5年总体获益率(治愈+改善)分别为89.54%、66.89%、61.53%.随访期间FMD组的总体治愈率高于TA组.结论 采用PTA及支架治疗儿童和青少年RAS安全可靠,且短期及长期临床获益良好.PTA治疗对于FMD患者获益程度大于TA患者.     

Percutaneous transluminal angioplasty for renovascular hypertension in children

Percutaneous transluminal angioplasty (PTA) has been developed over the past 8 years as an alternative to reconstructive surgery for renovascular hypertension. We report three cases and review the use of PTA in children with renal artery stenosis. At least 37 cases of PTA have been reported in patients whose ages ranged from 1.3 to 17 years (mean 10 years). Of these, 10 had fibromuscular dysplasia; 13 unspecified unilateral renal artery stenosis; 4 bilateral stenosis; 4 neurofibromatosis; 4 renal transplant; 1 atherosclerosis; and 1 postsurgical stenosis. Nine of 10 patients with fibromuscular dysplasia were cured and 3 of 4 with renal transplant arterial stenosis were cured or improved. There were 11 failures of PTA, including all 4 patients with neurofibromatosis and 1 with transplant arterial stenosis. We conclude that PTA is the treatment of choice for children with hypertension due to fibromuscular dysplasia and should be attempted for stenosis of the transplanted renal artery. Other lesions resulting in renal artery stenosis may not be as amenable to dilation and should be considered on an individual basis.R. L. Chevalier is an Established Investigator of the American Heart Association     

Cure and improvement of renovascular hypertension after percutaneous transluminal angioplasty of renal artery stenosis

In the present study we report our long-term experience in 82 patients with renovascular hypertension (48 with atherosclerotic stenosis, 34 with fibromuscular dysplasia) who were followed up for a mean observation period of 23.6 months after percutaneous transluminal angioplasty (PTA) of renal artery stenosis. Our results show a highly significant decrease in mean systolic and diastolic blood pressure. Cure rates were slightly higher in patients with fibromuscular dysplasia (41% cured, 47% improved) than in those with atherosclerosis (23% cured, 54% improved). Kidney function significantly improved in patients with cure, remained stable in those with improvement and worsened in cases classified as unimproved. These results document the good long-term effect of PTA on blood pressure and kidney function in patients with renal artery stenosis.     

Prognostic significance of intrarenal resistance indices in patients with renal artery interventions: a preliminary duplex sonographic study

No non-invasive test can predict the clinical outcome of renal revascularization procedures. Because duplex sonographic measurements of intrarenal flow patterns reflect the resistance to flow within the kidney, the prognostic value of the cortical end-diastolic to peak systolic (d/s) velocity ratio was investigated in patients undergoing intervention for renal artery stenosis. The clinical and duplex sonographic data on 32 patients with 35 interventions (30 percutaneous transluminal angioplasties and five operations) on 42 renal artery sides were analysed. Twenty-three patients had atherosclerotic renal artery stenosis and nine patients had fibromuscular dysplasia resulting in ≥60% renal artery stenosis. Measurements of the renal to aortic velocity ratio and cortical d/s ratio were performed before and after intervention. In the atherosclerotic patients, three interventions were clinically and technically successful, eight were technically successful but clinical failures, and 14 were clinically and technically unsuccessful. In the fibromuscular dysplasia patients, eight interventions were clinically and technically successful, and two were clinically and technically unsuccessful. The difference between the corresponding d/s ratios for atherosclerotic and fibromuscular dysplasia sides was significant on both the treated and not-treated sides (P < 0.02, two-tailed unpaired t-test). None of the 11 clinically successful procedures had a d/s ratio below 0.3, compared with seven values below 0.3 in the 24 clinically unsuccessful interventions (P = 0.05, one-tailed Fisher's exact test). It is concluded that: (1), a d/s ratio below 0.3 correlates with clinical failure in subsequent treatment of hypertension by renal revascularization, while a value above 0.3 has no prognostic significance; (2), despite technical success, not all atherosclerotic patients have clinical success from renal artery interventions; (3), in fibromuscular dysplasia patients, all clinical failures of renal artery interventions are associated with technical failures; and (4), the difference in d/s ratio between atherosclerotic and fibromuscular dysplasia patients may be a consequence of the more advanced age, longer duration of hypertension and additional risk factors in atherosclerotic patients.     

Nonsurgical treatment of renovascular hypertension by percutaneous transluminal angioplasty

A case of renovascular hypertension treated with percutaneous transluminal angioplasty is reported. Our patient was a 22-year-old housewife with 90 per cent stenosis of the right renal artery due to fibromuscular dysplasia. The renal artery was dilatated by percutaneous transluminal angioplasty with a Grützig balloon catheter to 25 per cent stenosis. Five hours after the procedure, blood pressure decreased from 180/114 mmHg to 130/95 mmHg; one day after, plasma renin activity fell from 4.7 ng/ml/hr to 1.7 ng/ml/hr. The patient was rehospitalized six months after percutaneous transluminal angioplasty to examine restenosis of the dilatated renal artery. Although her blood pressure remained normotensive and plasma renin activity was normal, replasty was performed since selective renal arteriography revealed 50 per cent stenosis.     

Transplant renal artery stenosis: experience and comparative results between surgery and angioplasty

One hundred thirty-eight patients with transplant renal artery stenosis (TRAS) were identified among 1200 patients undergoing renal transplantation in our university hospital. Severe systemic hypertension was the main symptom leading to a diagnosis of TRAS. Only 88 TRAS patients were given interventional treatment consisting of percutaneous angioplasty (PTA; n=49) or surgical repair (SR; n=39). The immediate success rate was 92.1% for SR and 69% for PTA. The long-term success rate was 81.5% for SR and 40.8% for PTA, with a follow-up period of 56.7±22.4 months (SR group) and 32±28.1 months (PTA group). PTA morbidity reached 28%, compared to 7.6% in the SR group. In spite of these results, we still favor PTA as a first line interventional treatment when TRAS is recent, linear, and distal and primary SR in cases of kinking and proximal TRAS.     

Results of renal artery balloon angioplasty limit its indications

Percutaneous transluminal balloon angioplasty (PTA) of 83 renal artery lesions in 55 patients was done because of renal failure in eight patients, hypertension in 35, renal failure and hypertension in 11, and polycythemia in one patient. Early results in 38 patients with arteriosclerosis showed five (13%) were worse and 13 (34%) were unchanged. Twenty patients (53%) with arteriosclerosis were initially cured or improved; however, seven of these patients had recurrence in 4 to 48 months. Ultimately, only 13 of 38 patients with arteriosclerosis (34%) were cured or improved (mean follow-up 22 months). Nine patients with fibromuscular dysplasia required 17 dilatations of arteries (three bilateral and five repeat), resulting in eight patients (89%) who were cured or improved. Selection of patients with hypertension by medical failure while receiving three or more hypertension medications or by lateralizing renal vein renin values yielded benefit in 17 of 26 patients (65%). Five of six patients with transplant stenosis of the renal artery and hypertension were cured or improved at mean follow-up of 18 months. Overall technical results of 83 artery dilatations were as follows: good, 58 (69%); fair, 10 (12%); poor or unsatisfactory, 16 (19%); these were judged with a blinded radiologic review. No patient suffered main renal artery thrombosis. There were 16 patients with complications of dilatation (morbidity rate of 29%). Nine patients subsequently had renal artery surgery from the same day to 64 days later with good results in all patients except one.(ABSTRACT TRUNCATED AT 250 WORDS)     

Randomized prospective study of effects of benazepril in renal transplantation: an analysis of safety and efficacy

Background. Prolonging the survival of transplanted kidneys is one of major tasks of modern nephrology. Angiotensin-converting enzyme inhibitors (ACEIs) compose a class of antihypertensive agents that has established efficacy in the treatment of hypertension and in slowing the progression of diabetic nephropathy and chronic glomerulonephritis. ACEIs are not widely accepted as a standard medication in the treatment of hypertension in renal transplant recipients because of the potential risk for decreased renal blood flow and glomerular filtration rate associated with a single kidney and concomitant cyclosporin use. Methods. We undertook a prospective randomized study of ACEI (benazepril) treatment in 76 posttransplant patients to determine the safety, efficacy, and side-effect profile of benazepril. Forty-one patients were assigned to the benazepril group and 35 patients were assigned to the control group. Results. The mean arterial blood pressure at a 12-month follow-up was lower than that at the time of initiation of benazepril or control therapy, with a decrease from 101 ± 10 mmHg to 94 ± 7 mmHg (P < 0.05) in the benazepril group and from 102 ± 12 mmHg to 94 ± 10 mmHg in the control group after 12 months of treatment. The serum creatinine concentrations did not change throughout the follow-up period. Conclusions. Benazepril was demonstrated to be an effective antihypertensive without any unfavorable effects on graft function. A significant antiproteinuric effect of benazepril was observed in patients with overt proteinuria. Further follow-up of this patient population will contribute to the establishment of the long-term renoprotective effect of benazepril in renal allograft recipients. Received: June 12, 2002 / Accepted: August 5, 2002 Correspondence to:T. Moriyama     

Minimally invasive salvage therapy for transplanted renal allografts

Abstract

Purpose: To evaluate the effectiveness of interventional therapy for complications of transplanted renal allografts. Materials and methods: Between January 2009 and March 2014, 14 patients underwent interventional therapy for complications of renal allografts. Complications included transplant renal artery stenosis (TRAS), TRAS combined with pseudoaneurysms, transplant renal venous kinking and ureteral obstruction (UO). Serum creatinine (S.Cr) levels were evaluated before and after procedure. The characteristics and procedure outcomes of these patients with vascular and nonvascular complications were also analyzed. Results: All primary procedures were successfully performed, which included percutaneous transluminal angioplasty (PTA) for TRAS (n?=?4), stenting and coil embolization for TRAS combined with pseudoaneurysms (n?=?1), stenting for renal vein kinking (n?=?2), and percutaneous nephrostomy (PCN) for UO (n?=?7) and secondary antegrade stent placement in six UO patients after 1 week of PCN. No major procedure related complications occurred. S.Cr level subsequently improved from 6.0?±?3.6 to 2.6?±?2.1?mg/dL (p?<?0.001), as well as patients’ clinical features within 1 week after procedure. In our study, the onset time of vascular complications was earlier (<6 months) than nonvascular complications with significant difference (p?<?0.001). During follow-up, the patient with TRAS and pseudoaneurysms suffered acute rejection 1 month after treatment and received transplant renal artery embolization. One patient with TRAS showed restenosis 4 months after procedure, and was retreated successfully with stenting. Thirteen cases reserved their transplanted renal allografts. Conclusion: Interventional therapy could be prior considered for transplanted renal allograft complications as its effectiveness and minimal invasiveness in saving the transplanted renal grafts.     

Role of intrarenal angiotensin II in glucocorticoid-induced renal vasodilation

Background. Although glucocorticoids elicit systemic hypertension, they are also demonstrated to cause marked increases in renal blood flow. The mechanism of this alteration, however, remains undetermined. Methods. Dogs were treated with dexamethasone (DEX) for 7 days, and renal, as well as systemic hemodynamic, responses to DEX were assessed. In addition, the role of intrarenal angiotensin (ANG) II in mediating the glucocorticoid-induced renal vasodilation was examined in conscious unrestrained dogs. Results. Seven-day treatment with DEX caused prominent increases in mean arterial pressure (MAP; from 80 ± 2 to 98 ± 5 mmHg) and in renal plasma flow (RPF; from 142 ± 4 to 191 ± 7 ml/min), with decreases in renal vascular resistance [RVR; from 0.26 ± 0.01 to 0.22 ± 0.01 mmHg/(ml/min)] and in the filtration fraction (FF; from 0.24 ± 0.01 to 0.20 ± 0.01). DEX treatment did not alter plasma ANG II levels, but enhanced candesartan-induced reduction in MAP. In contrast, the candesartan-induced increase in RPF (19 ± 2% increase) was completely abolished by DEX. DEX treatment markedly reduced renal tissue ANG II content (from 1.09 ± 0.07 to 0.71 ± 0.04 pg/mg tissue), which paralleled the response of renal tissue angiotensin-converting enzyme (ACE) activity (−20 ± 4%). Finally, intravenous ANG II administration caused a greater reduction in RPF during the DEX treatment period (−17 ± 2% vs −11 ± 1% in the control period). Conclusions. Glucocorticoids cause hypertension, but they also cause a paradoxical decrease in RVR and increase in RPF. The renal responses to candesartan and exogenous ANG II during DEX treatment suggest that the attenuation of intrarenal ANG-mediated vascular tone plays an important role in the altered renal hemodynamics. The decreased ANG tone is likely caused by reduced ANG II formation, resulting in part from suppressed ACE activity, but not from decreased sensitivity to ANG II. Received: November 1, 2000 / Accepted: April 5, 2001     

大通道内镜经单侧入路双侧减压治疗老年腰椎管狭窄症

目的:评价经大通道内镜系统单侧入路双侧减压治疗腰椎管狭窄症(lumbar spinal stenosis,LSS)的临床应用效果。方法:对2018年2月至2019年2月经大通道内镜系统单侧入路双侧减压治疗的32例LSS患者进行回顾性分析,男18例,女14例,年龄65~84(70.6±8.4)岁,病程1~12年。32例患者均伴有下肢麻木或疼痛,其中28例伴间歇性跛行,以下肢症状为著。狭窄节段:L3,42例,L4,519例,L5S113例,其中2例双节段狭窄。术前影像学资料显示中央管狭窄型3例,双侧侧隐窝狭窄型21例,混合狭窄型8例。记录手术用时及相关并发症发生情况,并于术后复查X线、CT和MRI;比较手术前后疼痛视觉模拟评分(visual analogue scale,VAS),Oswestry功能障碍指数(Oswestry Disability Index,ODI),单次连续步行距离(single continuous walking distance,SCWD),术后1年采用改良Macnab标准评价临床疗效。结果:32例患者均顺利完成手术并获得随访,手术时间70~160(85.64±11.94)min,随访时间12~24(17.68±2.43)个月。术中发生硬脊膜撕裂1例,术后减压通道对侧下肢短期内感觉障碍2例,均经相应处理后好转。术后影像学显示较术前责任节段的椎管明显扩大,神经根松解充分。术前及术后3 d,3个月,1年腰痛VAS评分分别为4.62±1.41,2.73±1.35,1.21±1.17,1.11±0.34;腿痛VAS评分分别为6.83±1.71,3.10±1.50,1.08±0.19,0.89±0.24。腰腿痛VAS评分术后各时间点与术前比较,差异均有统计学意义(P<0.05);术后3个月与术后3 d比较,差异也有统计学意义(P<0.05);术后1年与术后3个月比较,差异无统计学意义(P>0.05)。术前及术后3 d,3个月,1年ODI评分分别为38.40±6.48,18.42±2.40,5.48±0.77,3.05±0.28;SCWD分别为(47.48±5.32)m,(52.89±11.23)m,(245.43±18.94)m,(468.97±55.87)m。ODI评分及SCWD术后各时间点与术前比较,差异均有统计学意义(P<0.05);术后3个月与术后3 d及术后1年比较,差异也均有统计学意义(P<0.05)。术后1年采用Macnab标准评价疗效,结果优15例,良14例,可3例。结论:采用大通道后路经皮全脊柱内镜技术单侧入路双侧减压治疗LSS是安全、有效的术式,具有减压充分,创伤小、恢复快、安全性高及术后并发症发生率低等优点,可最大限度减少对腰椎稳定结构的破坏,是一种治疗腰椎管狭窄症的理想微创手术。